Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230639893> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4230639893 endingPage "335" @default.
- W4230639893 startingPage "332" @default.
- W4230639893 abstract "Her-2/neu or c-erbB-2, a 185-kD protein is an important prognostic indicator/target for therapy in metastatic breast carcinoma. Recent reports have also identified a role for Her-2/neu overexpression in other solid tumors. We performed a retrospective analysis to evaluate the prevalence and prognostic role of Her-2/neu overexpression in patients with glioblastoma multiforme (GBM). Data collection (chart review) included demographic information, symptoms at presentation, histologic grade, survival time, and treatment offered. Testing for Her-2/neu overexpression was performed on paraffin-embedded archival tumor tissue using immunohistochemistry (IHC) (Hercep test). An IHC score of 2+ or greater was considered overexpression. An experienced pathologist who was blinded from the clinical history performed all the IHC testing. Between 1990 and 2001, 149 subjects (68 females, 81 males) with a biopsy-proven diagnosis of GBM were identified. Age range was 26 to 79 years (mean: 64 years) and overall mean survival was 12 months. Her-2/neu overexpression was detected in 23 patients (15.4%). Interestingly, the median survival for patients whose pathologic specimens revealed Her-2/neu overexpression was 4 months compared to those who lacked overexpression, in whom survival was 8 months. After adjusting for age, performance status, smoking history, and treatment, logistic regression analysis (with a survival of <3 months as the dependent variable) revealed that Her-2/neu overexpression significantly (p < 0.01) increased the odds of early mortality (<3 months). The results of our large study indicate that Her-2/neu overexpression may be a poor prognostic marker in patients with GBM. In addition, in a proportion of subjects (15.4%), Her-2/neu may be a potential target for tumor-specific monoclonal antibody therapy. The role of trastuzumab (alone or in combination with conventional therapy) needs to be evaluated." @default.
- W4230639893 created "2022-05-11" @default.
- W4230639893 creator A5030450361 @default.
- W4230639893 creator A5037627410 @default.
- W4230639893 creator A5048770508 @default.
- W4230639893 creator A5049519740 @default.
- W4230639893 creator A5064990019 @default.
- W4230639893 creator A5082300423 @default.
- W4230639893 creator A5085556853 @default.
- W4230639893 date "2003-08-01" @default.
- W4230639893 modified "2023-09-23" @default.
- W4230639893 doi "https://doi.org/10.1097/00000421-200308000-00004" @default.
- W4230639893 hasPublicationYear "2003" @default.
- W4230639893 type Work @default.
- W4230639893 citedByCount "4" @default.
- W4230639893 countsByYear W42306398932012 @default.
- W4230639893 countsByYear W42306398932021 @default.
- W4230639893 crossrefType "journal-article" @default.
- W4230639893 hasAuthorship W4230639893A5030450361 @default.
- W4230639893 hasAuthorship W4230639893A5037627410 @default.
- W4230639893 hasAuthorship W4230639893A5048770508 @default.
- W4230639893 hasAuthorship W4230639893A5049519740 @default.
- W4230639893 hasAuthorship W4230639893A5064990019 @default.
- W4230639893 hasAuthorship W4230639893A5082300423 @default.
- W4230639893 hasAuthorship W4230639893A5085556853 @default.
- W4230639893 hasConcept C10515644 @default.
- W4230639893 hasConcept C121608353 @default.
- W4230639893 hasConcept C126322002 @default.
- W4230639893 hasConcept C142724271 @default.
- W4230639893 hasConcept C143998085 @default.
- W4230639893 hasConcept C151956035 @default.
- W4230639893 hasConcept C167135981 @default.
- W4230639893 hasConcept C204232928 @default.
- W4230639893 hasConcept C2775934546 @default.
- W4230639893 hasConcept C2776872082 @default.
- W4230639893 hasConcept C530470458 @default.
- W4230639893 hasConcept C71924100 @default.
- W4230639893 hasConcept C90924648 @default.
- W4230639893 hasConceptScore W4230639893C10515644 @default.
- W4230639893 hasConceptScore W4230639893C121608353 @default.
- W4230639893 hasConceptScore W4230639893C126322002 @default.
- W4230639893 hasConceptScore W4230639893C142724271 @default.
- W4230639893 hasConceptScore W4230639893C143998085 @default.
- W4230639893 hasConceptScore W4230639893C151956035 @default.
- W4230639893 hasConceptScore W4230639893C167135981 @default.
- W4230639893 hasConceptScore W4230639893C204232928 @default.
- W4230639893 hasConceptScore W4230639893C2775934546 @default.
- W4230639893 hasConceptScore W4230639893C2776872082 @default.
- W4230639893 hasConceptScore W4230639893C530470458 @default.
- W4230639893 hasConceptScore W4230639893C71924100 @default.
- W4230639893 hasConceptScore W4230639893C90924648 @default.
- W4230639893 hasIssue "4" @default.
- W4230639893 hasLocation W42306398931 @default.
- W4230639893 hasOpenAccess W4230639893 @default.
- W4230639893 hasPrimaryLocation W42306398931 @default.
- W4230639893 hasRelatedWork W2055804777 @default.
- W4230639893 hasRelatedWork W2098891062 @default.
- W4230639893 hasRelatedWork W2224319365 @default.
- W4230639893 hasRelatedWork W2357091074 @default.
- W4230639893 hasRelatedWork W2989121736 @default.
- W4230639893 hasRelatedWork W317834158 @default.
- W4230639893 hasRelatedWork W4220726198 @default.
- W4230639893 hasRelatedWork W4256227745 @default.
- W4230639893 hasRelatedWork W75229661 @default.
- W4230639893 hasRelatedWork W2555822460 @default.
- W4230639893 hasVolume "26" @default.
- W4230639893 isParatext "false" @default.
- W4230639893 isRetracted "false" @default.
- W4230639893 workType "article" @default.